Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BIIB 
Biogen Inc (BIIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: BIIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
37 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $171.85
Year Target Price $171.85
| 13 | Strong Buy |
| 4 | Buy |
| 20 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.57% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.47B USD | Price to earnings Ratio 12.46 | 1Y Target Price 172.2 |
Price to earnings Ratio 12.46 | 1Y Target Price 172.2 | ||
Volume (30-day avg) - | Beta 0.15 | 52 Weeks Range 110.04 - 238.00 | Updated Date 06/29/2025 |
52 Weeks Range 110.04 - 238.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.07% | Operating Margin (TTM) 28.05% |
Management Effectiveness
Return on Assets (TTM) 5.43% | Return on Equity (TTM) 9.19% |
Valuation
Trailing PE 12.46 | Forward PE 8.44 | Enterprise Value 22497129058 | Price to Sales(TTM) 1.88 |
Enterprise Value 22497129058 | Price to Sales(TTM) 1.88 | ||
Enterprise Value to Revenue 2.29 | Enterprise Value to EBITDA 8.32 | Shares Outstanding 146528000 | Shares Floating 146133672 |
Shares Outstanding 146528000 | Shares Floating 146133672 | ||
Percent Insiders 0.22 | Percent Institutions 92.96 |
Analyst Ratings
Rating 3.81 | Target Price 171.85 | Buy 4 | Strong Buy 13 |
Buy 4 | Strong Buy 13 | ||
Hold 20 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biogen Inc
Company Overview
History and Background
Biogen Inc. was founded in 1978 in Geneva, Switzerland, and is one of the worldu2019s first global biotechnology companies. It pioneered new scientific approaches to discover, develop, and deliver worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases and related therapeutic adjacencies. Key milestones include the development of Avonex, the first approved treatment for multiple sclerosis, and the expansion into other therapeutic areas like spinal muscular atrophy and Alzheimer's disease.
Core Business Areas
- Neurology: Focuses on developing therapies for neurological diseases, including multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease.
- Biosimilars: Develops and commercializes biosimilars, which are follow-on versions of innovator biologic drugs.
Leadership and Structure
The CEO is Christopher A. Viehbacher. Biogen has a board of directors and operates through various departments including research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Tysabri: A treatment for relapsing forms of multiple sclerosis. Competitors include Roche's Ocrevus, Novartis' Gilenya, and Sanofi's Aubagio.
- Spinraza: A treatment for spinal muscular atrophy (SMA). Competitors include Novartis' Zolgensma and Roche's Evrysdi.
- Aduhelm: An Alzheimer's disease treatment, generating limited revenue and facing significant market access challenges and competition from Eisai's Leqembi.
- Tecfidera: An oral medication for relapsing-remitting multiple sclerosis. Competitors include other oral MS drugs. The drug has lost market share due to generic entrants.
- Vumerity: An oral medication for relapsing forms of multiple sclerosis, designed with improved gastrointestinal tolerability compared to Tecfidera. Competitors include Roche's Ocrevus, Novartis' Gilenya, and Sanofi's Aubagio.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and a complex regulatory environment. Key trends include the growth of biologics and biosimilars, personalized medicine, and gene therapy.
Positioning
Biogen is a major player in the neurology space, particularly in MS and SMA. It faces increasing competition and pricing pressures.
Total Addressable Market (TAM)
The TAM for neurology and neurodegenerative diseases is substantial and growing, estimated at hundreds of billions of dollars. Biogen's position varies across different therapeutic areas, facing strong competition in MS but holding a significant position in SMA.
Upturn SWOT Analysis
Strengths
- Strong position in MS and SMA markets
- Established R&D capabilities
- Experience in developing and commercializing complex biologics
- Global presence
- Pipeline of potential new therapies
Weaknesses
- Reliance on a few key products
- Exposure to generic competition
- Controversy surrounding Aduhelm's efficacy and pricing
- Dependence on partners to discover and produce drugs
Opportunities
- Expansion into new therapeutic areas (e.g., Alzheimer's disease)
- Development of biosimilars
- Strategic partnerships and acquisitions
- Growing demand for neurological therapies
- New drug development in the pipeline.
Threats
- Increasing competition from biosimilars and generics
- Pricing pressures from payers
- Regulatory challenges
- Clinical trial failures
- Slower than expected adoption of new drugs
Competitors and Market Share
Key Competitors
- RHHBY
- NVS
- SNY
- ESAIY
Competitive Landscape
Biogen faces intense competition in its core markets. Its advantages include established brands and expertise in neurology, but it faces challenges from larger, more diversified pharmaceutical companies.
Major Acquisitions
Reata Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 7300
- Strategic Rationale: This acquisition of Reata provides Biogen with Skyclarys, a drug that treats Friedreich's ataxia, a rare neurodegenerative disease. This strengthens Biogen's neurology portfolio and offers a potential new revenue stream.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by key products like Tysabri and Spinraza, but has been impacted by generic competition and the controversy surrounding Aduhelm.
Future Projections: Future growth is dependent on pipeline success, market acceptance of new products, and strategic partnerships. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include focusing on R&D investments in neurology and immunology, streamlining operations, and exploring strategic partnerships.
Summary
Biogen faces both opportunities and challenges in the biotechnology industry. While it has a strong position in neurology and R&D capabilities, generic competition and regulatory hurdles hinder growth. Key to its future success lies in capitalizing on its pipeline and strategically allocating capital to enhance its value proposition. A critical aspect for Biogen is successfully navigating the evolving regulatory landscape and effectively marketing its new products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biogen Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1991-09-16 | President, CEO & Director Mr. Christopher A. Viehbacher | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 7605 | Website https://www.biogen.com |
Full time employees 7605 | Website https://www.biogen.com | ||
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.